Nursing Care Plan for Malaria: Key Strategies

The five main NANDA-I diagnoses applicable to malaria, in order of priority, are: (1) Hyperthermia — related to systemic response to Plasmodium infection and rupture of erythrocytes releasing pyrogens, as evidenced by temperature above 38.5°C, tachycardia and chills; this is first priority because the cyclical fever spikes (classic 48-hour cycle in P. vivax/ovale, 72-hour in P. malariae) can reach 40–41°C and trigger febrile seizures. (2) Deficient Fluid Volume — related to profuse sweating during fever defervescence, vomiting, and reduced oral intake, as evidenced by dry mucous membranes, decreased urine output and elevated haematocrit; dehydration accelerates haemodynamic compromise. (3) Impaired Tissue Perfusion — related to destruction of red blood cells by the parasite causing haemolytic anaemia, as evidenced by pallor, weakness, and low haemoglobin; in P. falciparum this can progress to cerebral malaria if parasitized cells block cerebral capillaries. (4) Risk for Bleeding — related to thrombocytopaenia (low platelet count) caused by splenic sequestration and immune-mediated platelet destruction; monitor for petechiae, bruising and bleeding gums. (5) Acute Pain — related to myalgia, arthralgia and headache associated with the febrile phase. In GNM/BSc Nursing examinations, always prioritise by Maslow: physiological threats (oxygenation, fluid) before safety, before psychosocial.

The febrile phase of malaria requires concurrent temperature management, fluid replacement, drug administration, and close monitoring — all happening within the same nursing shift. Temperature management: monitor temperature every 1–2 hours during a fever spike; administer paracetamol 650 mg (or as prescribed) for temperature above 38.5°C and document the response; use tepid sponging (30°C water) and a fan; avoid cold water or alcohol sponging (causes shivering and paradoxically raises core temperature). Fluid management: encourage 2–3 litres of oral fluid per day; if the patient is vomiting or obtunded, prepare for IV therapy — Normal Saline or Ringer's Lactate, monitoring intake and output hourly in severe malaria. Antimalarial drug administration: administer as prescribed (Artemisinin-based Combination Therapy — ACT — for P. falciparum; chloroquine or primaquine for P. vivax, with G6PD test required before primaquine to avoid haemolytic reaction); give with food to reduce nausea; do not crush chloroquine tablets. Monitoring: check haemoglobin and platelet count daily in severe malaria; observe for warning signs of cerebral malaria (confusion, seizures, altered GCS) and severe anaemia (Hb below 7 g/dL); check blood glucose in patients on quinine (hypoglycaemia risk); assess urine colour — dark or cola-coloured urine indicates blackwater fever (severe haemolysis) and requires immediate escalation. Document all observations and drug administration times accurately.

Distinguishing severe from uncomplicated malaria is a critical clinical nursing skill because severe malaria requires immediate escalation and IV antimalarials rather than oral ACT. WHO defines severe malaria (almost always P. falciparum) by the presence of one or more of these criteria: (1) Impaired consciousness or unrousable coma — GCS below 10; (2) Prostration — inability to sit up or stand without support in a child who was previously able to; (3) Multiple convulsions — more than 2 within 24 hours; (4) Respiratory distress — deep laboured breathing (acidotic breathing / Kussmaul pattern); (5) Circulatory collapse — systolic BP below 70 mmHg, cold extremities; (6) Abnormal bleeding — spontaneous bleeding from gums, nose or IV sites; (7) Severe anaemia — Hb below 7 g/dL with high parasite density; (8) Haemoglobinuria — dark or black urine without urinary tract infection; (9) Pulmonary oedema confirmed by chest X-ray; (10) Hypoglycaemia — blood glucose below 2.2 mmol/L. Uncomplicated malaria presents with fever, chills, headache, myalgia, vomiting and a positive blood film or RDT — but the patient is conscious, haemodynamically stable, and can tolerate oral medications. Nursing action for severe malaria: immediately notify the physician, prepare IV access, draw blood for FBC, blood glucose, renal and liver function, blood culture, and group and crossmatch; position the patient on their side to protect the airway; have oxygen and emergency resuscitation equipment ready.

Prevention education is essential because malaria relapse (P. vivax has a liver-stage that causes relapse months later) and reinfection are common. Cover five areas: (1) Completing the full drug course — emphasise that stopping antimalarials early because symptoms resolved is the main cause of treatment failure and relapse; for P. vivax, primaquine must be taken for 14 days after the acute phase to eliminate liver-stage parasites (hypnozoites). (2) Mosquito bite prevention — Anopheles mosquitoes bite between dusk and dawn; advise: sleep under a long-lasting insecticidal net (LLIN/ITBN); use DEET-based repellent on exposed skin at night; wear long-sleeved shirts and trousers after sunset; screen windows and doors; eliminate standing water around the home (flowerpots, blocked drains, discarded tyres) where mosquitoes breed. (3) Recognising relapse — P. vivax malaria can recur weeks to months after treatment; teach the patient to seek an RDT or blood smear test if fever with chills returns, and not to self-medicate without confirmation. (4) Travel precautions — if travelling to high-risk areas, take malaria chemoprophylaxis as recommended by a doctor; chemoprophylaxis is different from treatment and must be started before travel. (5) Community role — report suspected cases in the household to the local health worker (ASHA, ANM); indoor residual spraying (IRS) by the health department is a household right in endemic areas.